| 10.27.21 | Merck's making ready-to-use versions of antibody products; Novartis-backed Credence ups production

Klicken Sie hier, um Fiercebiotech.com zu abonnieren

Laden...

3 jahre vor

Html
Text

Exec Summary: Is My Molecule Suitable for an Orally Disintegrating Tablet

Download this executive summary to learn more on the factors to consider when evaluating Orally Disintegrating Tablets (ODTs) as a potential dose form. Download today.

Today's Rundown

Merck taps Xeris for ready-to-use versions of antibody products Novartis-backed Credence taps Phillips-Medisize to step up production drug delivery system FDA greenlights Genentech's eye implant for macular degeneration. Will it be a tough sell? AmMax, targeting a Daiichi market, posts data on delivery of rare tumor drug Ligand licenses prodrug tech to oral COVID-19 antiviral project Top 10 drug launch disasters

Featured Story

Merck taps Xeris for ready-to-use versions of antibody products

By Nick Paul Taylor

Merck has tapped Xeris Pharmaceuticals to help reformulate some of its drugs. The deal gives Merck a chance to license a Xeris technology to develop ultra-high concentration, ready-to-use formulations of certain monoclonal antibodies.

Webinar: Clinical Adjudication Survey Results Revealed

Tuesday, November 2 | 1pm ET / 10am PT

In a recent survey, 89% of clinical adjudication users agreed clinical adjudication provides value to clinical trials. Join two Bioclinica experts for a discussion of these and other survey results to understand how they could impact your studies. Register Now.

Novartis-backed Credence taps Phillips-Medisize to step up production drug delivery system

By Nick Paul Taylor

Credence MedSystems has hit upon a way to scale up production of its drug delivery system. Weeks after disclosing $40 million from investors including Novartis, Credence has unveiled a partnership with Phillips-Medisize to step up from a clinical line to large-scale manufacturing.

FDA greenlights Genentech's eye implant for macular degeneration. Will it be a tough sell?

By Kevin Dunleavy

The FDA has approved Genentech’s Susvimo, a port delivery system with Roche’s ranibizumab in patients with wet age-related macular degeneration. Now the trick could be to get patients to accept an implant the size of a grain of rice placed under the upper eyelid that delivers doses of Lucentis and is refilled every six months.

AmMax, targeting a Daiichi market, posts data on delivery of rare tumor drug

By Nick Paul Taylor

AmMax Bio's attempt to muscle in on a market monopolized by Daiichi Sankyo has advanced, with the biotech posting midphase data on the effect of injecting an antibody into the joints of patients with rare tumors.

Ligand licenses prodrug tech to oral COVID-19 antiviral project

By Nick Paul Taylor

Ligand Pharmaceuticals wants another piece of the COVID-19 pie. Having been one of the companies behind Gilead’s Veklury, Ligand has positioned itself to support an oral COVID-19 antiviral through a deal with China Resources Double-Crane Pharmaceutical (CRDC).

Top 10 drug launch disasters

By Angus Liu

An estimated 40% of drugs approved between 2004 and 2016 underperformed, according to Wall Street’s prelaunch sales forecasts. That's a lousy track record, given that a strong launch is critical to a drug's success. Here, we list 10 drug launches from the past five years that suffered the most noteworthy failures.

Article: Putting Patients First When Manufacturing OSD Forms

Around 35% of the general population has difficulty swallowing. Read how orally disintegrating tablets (ODT) can help & why Zydis ODT platform is a game changer. Read today.